Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 17Active not recruiting 10Terminated 9Recruiting 8Unknown 2Not yet recruiting 2Withdrawn 1Suspended 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Ovarian Neoplasms 3Prostatic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Neoplasm Metastasis 1Microsatellite-stable Colorectal Cancer 1Melanoma 1Lymphoma, B-Cell 1Lung Neoplasms 1Glioblastoma 1Genital Neoplasms, Female 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Hepatocellular 1Advanced Renal Cell Carcinoma 1Adenocarcinoma of Lung 1

Interventions

aldesleukin 1Nivolumab 1Interleukin-2 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Carcinoma, Transitional Cell × Nivolumab × Clear all
NCT03970382 2022-08-18

A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors

PACT Pharma, Inc.

Phase 1 Suspended
21 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Melanoma, Ovarian Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡